Pharmacologic considerations for therapeutic success with antiretroviral agents

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

OBJECTIVE: To explore pharmacologic elements that contribute to therapeutic success with agents used for the treatment of HIV DATA SOURCES: Primary articles were identified through MEDLINE (January 1990-January 1999) and second sources. Conference abstracts were selected by review of published proceedings. STUDY SELECTION AND DATA EXTRACTION: The author evaluated all articles, and relevant information was selected for incorporation into this review. DATA SYNTHESIS: Heterogeneity in the response to antiretroviral therapy has been attributed to virologic, immunologic, behavioral, and pharmacologic differences among patients. Patients receiving the same dose of an antiretroviral agent will not have the same systemic or intracellular concentration because of interpatient variability in drug absorption, distribution, metabolism, and excretion. Pharmacologic theory and available clinical data support relationships between drug concentration and anti-HIV effect. Thus, variability in drug concentrations contributes to variability in antiviral effect. Desirable pharmacologic characteristics for an antiretroviral drug include high oral bioavailability, a long elimination half-life, low intra- and interpatient pharmacokinetic variability, and a predictable dose-concentration-effect relationship CONCLUSIONS: Treatment of the individual who is infected with HIV is a challenging long-term undertaking. Optimal management requires synthesis of a rapidly evolving base of basic and clinical knowledge. The selection of an antiretroviral regimen based on an understanding of the degree to which each individual agent possesses the desired pharmacologic characteristics should help the healthcare provider to translate the therapeutic principles of treatment of HIV infection into clinical reality for all patients.

Original languageEnglish (US)
Pages (from-to)989-995
Number of pages7
JournalAnnals of Pharmacotherapy
Volume33
Issue number9
DOIs
StatePublished - Sep 15 1999

Fingerprint

Anti-Retroviral Agents
Therapeutics
HIV
Pharmaceutical Preparations
Anti-HIV Agents
MEDLINE
Health Personnel
Biological Availability
HIV Infections
Antiviral Agents
Half-Life
Pharmacokinetics

Keywords

  • Antiretrovirals
  • Human immunodeficiency virus

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacologic considerations for therapeutic success with antiretroviral agents. / Fletcher, Courtney V.

In: Annals of Pharmacotherapy, Vol. 33, No. 9, 15.09.1999, p. 989-995.

Research output: Contribution to journalArticle

@article{f0980ff46ea542298be0368231ced3d6,
title = "Pharmacologic considerations for therapeutic success with antiretroviral agents",
abstract = "OBJECTIVE: To explore pharmacologic elements that contribute to therapeutic success with agents used for the treatment of HIV DATA SOURCES: Primary articles were identified through MEDLINE (January 1990-January 1999) and second sources. Conference abstracts were selected by review of published proceedings. STUDY SELECTION AND DATA EXTRACTION: The author evaluated all articles, and relevant information was selected for incorporation into this review. DATA SYNTHESIS: Heterogeneity in the response to antiretroviral therapy has been attributed to virologic, immunologic, behavioral, and pharmacologic differences among patients. Patients receiving the same dose of an antiretroviral agent will not have the same systemic or intracellular concentration because of interpatient variability in drug absorption, distribution, metabolism, and excretion. Pharmacologic theory and available clinical data support relationships between drug concentration and anti-HIV effect. Thus, variability in drug concentrations contributes to variability in antiviral effect. Desirable pharmacologic characteristics for an antiretroviral drug include high oral bioavailability, a long elimination half-life, low intra- and interpatient pharmacokinetic variability, and a predictable dose-concentration-effect relationship CONCLUSIONS: Treatment of the individual who is infected with HIV is a challenging long-term undertaking. Optimal management requires synthesis of a rapidly evolving base of basic and clinical knowledge. The selection of an antiretroviral regimen based on an understanding of the degree to which each individual agent possesses the desired pharmacologic characteristics should help the healthcare provider to translate the therapeutic principles of treatment of HIV infection into clinical reality for all patients.",
keywords = "Antiretrovirals, Human immunodeficiency virus",
author = "Fletcher, {Courtney V.}",
year = "1999",
month = "9",
day = "15",
doi = "10.1345/aph.19075",
language = "English (US)",
volume = "33",
pages = "989--995",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Pharmacologic considerations for therapeutic success with antiretroviral agents

AU - Fletcher, Courtney V.

PY - 1999/9/15

Y1 - 1999/9/15

N2 - OBJECTIVE: To explore pharmacologic elements that contribute to therapeutic success with agents used for the treatment of HIV DATA SOURCES: Primary articles were identified through MEDLINE (January 1990-January 1999) and second sources. Conference abstracts were selected by review of published proceedings. STUDY SELECTION AND DATA EXTRACTION: The author evaluated all articles, and relevant information was selected for incorporation into this review. DATA SYNTHESIS: Heterogeneity in the response to antiretroviral therapy has been attributed to virologic, immunologic, behavioral, and pharmacologic differences among patients. Patients receiving the same dose of an antiretroviral agent will not have the same systemic or intracellular concentration because of interpatient variability in drug absorption, distribution, metabolism, and excretion. Pharmacologic theory and available clinical data support relationships between drug concentration and anti-HIV effect. Thus, variability in drug concentrations contributes to variability in antiviral effect. Desirable pharmacologic characteristics for an antiretroviral drug include high oral bioavailability, a long elimination half-life, low intra- and interpatient pharmacokinetic variability, and a predictable dose-concentration-effect relationship CONCLUSIONS: Treatment of the individual who is infected with HIV is a challenging long-term undertaking. Optimal management requires synthesis of a rapidly evolving base of basic and clinical knowledge. The selection of an antiretroviral regimen based on an understanding of the degree to which each individual agent possesses the desired pharmacologic characteristics should help the healthcare provider to translate the therapeutic principles of treatment of HIV infection into clinical reality for all patients.

AB - OBJECTIVE: To explore pharmacologic elements that contribute to therapeutic success with agents used for the treatment of HIV DATA SOURCES: Primary articles were identified through MEDLINE (January 1990-January 1999) and second sources. Conference abstracts were selected by review of published proceedings. STUDY SELECTION AND DATA EXTRACTION: The author evaluated all articles, and relevant information was selected for incorporation into this review. DATA SYNTHESIS: Heterogeneity in the response to antiretroviral therapy has been attributed to virologic, immunologic, behavioral, and pharmacologic differences among patients. Patients receiving the same dose of an antiretroviral agent will not have the same systemic or intracellular concentration because of interpatient variability in drug absorption, distribution, metabolism, and excretion. Pharmacologic theory and available clinical data support relationships between drug concentration and anti-HIV effect. Thus, variability in drug concentrations contributes to variability in antiviral effect. Desirable pharmacologic characteristics for an antiretroviral drug include high oral bioavailability, a long elimination half-life, low intra- and interpatient pharmacokinetic variability, and a predictable dose-concentration-effect relationship CONCLUSIONS: Treatment of the individual who is infected with HIV is a challenging long-term undertaking. Optimal management requires synthesis of a rapidly evolving base of basic and clinical knowledge. The selection of an antiretroviral regimen based on an understanding of the degree to which each individual agent possesses the desired pharmacologic characteristics should help the healthcare provider to translate the therapeutic principles of treatment of HIV infection into clinical reality for all patients.

KW - Antiretrovirals

KW - Human immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=0032845172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845172&partnerID=8YFLogxK

U2 - 10.1345/aph.19075

DO - 10.1345/aph.19075

M3 - Article

C2 - 10492504

AN - SCOPUS:0032845172

VL - 33

SP - 989

EP - 995

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -